Corona Virus Vaccine Market Emerging Growth By Top Players AstraZeneca plc, Pfizer Inc., Sanofi S.A., Novavax, Inc., Moderna, Inc., Sinovac Biotech Ltd., Bharat Biotech International Limited, Johnson & Johnson, BioNTech SE, Serum Institute of India

Government of various countries are taking actions, in order to ensure the rapid production and delivery of the COVID-19 vaccines once approved by regulatory authorities for marketing and commercialization. For instance, on May 15, 2020, the U.S. government announced Framework and Leadership for 'Operation Warp Speed', a national program to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics (medical countermeasures) in the U.S.

PDF Brochure of This Business Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/4320

The Operation Warp Speed's goal is to produce and deliver around 300 million doses of safe and effective COVID-19 vaccines with the initial doses available by January 2021 in the U.S. The Operation Warp Speed (OWS) is formed by the partnership of Department of Health and Human Services (HHS) such as Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), and the Department of Defense (DoD).

Month Actions To Support OWP
Vaccine Development Manufacturing Distribution
March The United States Department of Health & Human Services (HHS) announced US$ 456 million in funds for Johnson & Johnson's (Janssen) candidate vaccine. -
April HHS funded nearly US$ 483 million in support for Moderna's candidate vaccine -
May HHS provided around US$ 1.2 billion in support for AstraZeneca's candidate vaccine Department of Defense (DoD) and HHS entered into a US$ 138 million contract with ApiJect for over 100 million prefilled syringes for distribution across the U.S. by year-end 2020
June HHS announced a task order with Emergent BioSolutions for the advancement of domestic manufacturing capabilities and capacity for potential COVID-19 vaccine & therapeutics. HHS and DoD announced a joint effort to expand the manufacturing capacity for vials that may be needed for vaccines and treatments
July
HHS funded US$ 1.6 billion in funds to support the large-scale manufacturing of Novavax's vaccine candidate.

HHS announced a collaboration with Texas A&M University and FUJIFILM for the advancement of domestic manufacturing capabilities and capacity for potential COVID-19 vaccine using another BARDA-supported Center for Innovation in Advanced Department and Manufacturing
August HHS announced a fund of approximately US$ 1 billion to support the large-scale manufacturing and delivery of Johnson & Johnson's (Janssen) investigational vaccine candidate. HHS & DoD announced that McKesson Corporation will be central distributor of future COVID-19 vaccines and related supplies
September HHS and DoD released two documents outlining detailed strategy to deliver safe and effective COVID-19 vaccine doses in the U.S.
October HHS entered into an agreement with Cytiva for the expansion of the company’s manufacturing capacity for products that are essential in producing COVID-19 vaccines The agreements with CVS and Walgreens to provide and administer COVID-19 vaccines to residents of long-term care facilities (LTCF) in the U.S.
November HHS and DoD announced partnerships with large chain pharmacies and networks, covering around 60% of pharmacies throughout the 50 states, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands.

Request For Customization Of This Business Research Report:
https://www.coherentmarketinsights.com/insight/request-customization//4320

Key Players

Major players operating in the global corona virus vaccine market include AstraZeneca plc, Pfizer Inc., Sanofi S.A., Novavax, Inc., Moderna, Inc., Sinovac Biotech Ltd., Bharat Biotech International Limited, Johnson & Johnson, BioNTech SE, Serum Institute of India, Shanghai Fosun Pharmaceutical Group Co., Ltd., CanSino Biologics Inc., CureVac AG, Cadila Healthcare Limited, Arcturus Therapeutics Holdings Inc., Entos Pharmaceuticals, and Symvivo.

By Vaccine Type:
Inactivated Virus
Protein Subunit
Non-replicating Viral Vector
Repurposed Vaccines
RNA Vaccine
DNA Vaccine
Genetic Vaccines

Apply Promo Code “STAYHOME” and Get Up to 30% Discount

Buy This Complete A Business Report:
https://www.coherentmarketinsights.com/insight/buy-now/4320

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.